title: What Is a Clinically Relevant Improvement in Quality of Life in Adults With ADHD?
abstract: To estimate a minimal clinically important difference (MCID) on the adult ADHD Quality of Life (AAQoL) scale.
  
  
  
  The MCID was determined from data from short-term ( N = 537) and long-term ( N = 440), placebo-controlled atomoxetine trials in adults with ADHD. For the anchor-based approach, change in clinician-rated Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S) scores was used to derive MCID. For the distribution-based approach, baseline-to-endpoint mean ( SD) changes in AAQoL scores corresponding to 0.5 SD were computed.
  
  
  
  The MCID was similar (approximately 8-point difference) between the short-term and the long-term treatment groups when either the anchor-based or distribution-based approach was used.
  
  
  
  These results suggest that approximately 8 points in the change from baseline on the AAQoL is a MCID.
authors: 1 Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
authors: Yoko
authors: Y
authors: Tanaka
authors: 2 The Brod Group, Mill Valley, CA, USA.
authors: Meryl
authors: M
authors: Brod
authors: 3 inVentiv Health, Indianapolis, IN, USA.
authors: Jeannine R
authors: JR
authors: Lane
authors: 1 Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
authors: Himanshu
authors: H
authors: Upadhyaya
mesh_terms: D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000069445:Atomoxetine Hydrochloride / Q000627:therapeutic use; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy / Q000523:psychology*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000069445:Atomoxetine Hydrochloride
keywords: ADHD; atomoxetine; attention deficit/hyperactivity disorder; quality of life